Ghent University Academic Bibliography

Advanced

A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo

Hien Anh Nguyen, Ying Su, Jenny Yu Zhang, Aleksandar Antanasijevic, Michael Caffrey, Amanda M Schalk, Li Liu, Damiano Rondelli, Annie Oh, Dolores L Mahmud, et al. (2018) CANCER RESEARCH. 78(6). p.1549-1560
abstract
Acute lymphoblastic leukemia (ALL) is the most common type of pediatric cancer, although about 4 of every 10 cases occur in adults. The enzyme drug L-asparaginase serves as a cornerstone of ALL therapy and exploits the asparagine dependency of ALL cells. In addition to hydrolyzing the amino acid L-asparagine, all FDA-approved L-asparaginases also have significant L-glutaminase coactivity. Since several reports suggest that L-glutamine depletion correlates with many of the side effects of these drugs, enzyme variants with reduced L-glutaminase coactivity might be clinically beneficial if their antileukemic activity would be preserved. Here we show that novel low L-glutaminase variants developed on the backbone of the FDA-approved Erwinia chrysanthemi L-asparaginase were highly efficacious against both T-and B-cell ALL, while displaying reduced acute toxicity features. These results support the development of a new generation of safer L-asparaginases without L-glutaminase activity for the treatment of human ALL. Significance: A newL-asparaginase-based therapy is less toxic compared with FDA-approved high L-glutaminase enzymes
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
CHRYSANTHEMI L-ASPARAGINASE, ACUTE LYMPHOCYTIC-LEUKEMIA, POLYETHYLENE-GLYCOL, CLINICAL-EVALUATION, ESCHERICHIA-COLI, CHILDREN, SYNTHETASE, TOXICITY, THERAPY, ENZYME
journal title
CANCER RESEARCH
Cancer Res.
volume
78
issue
6
pages
1549 - 1560
Web of Science type
Article
Web of Science id
000427620900016
ISSN
0008-5472
1538-7445
DOI
10.1158/0008-5472.can-17-2106
language
English
UGent publication?
yes
classification
U
copyright statement
I don't know the status of the copyright for this publication
id
8551637
handle
http://hdl.handle.net/1854/LU-8551637
date created
2018-02-23 08:16:24
date last changed
2018-07-13 13:50:14
@article{8551637,
  abstract     = {Acute lymphoblastic leukemia (ALL) is the most common type of pediatric cancer, although about 4 of every 10 cases occur in adults. The enzyme drug L-asparaginase serves as a cornerstone of ALL therapy and exploits the asparagine dependency of ALL cells. In addition to hydrolyzing the amino acid L-asparagine, all FDA-approved L-asparaginases also have significant L-glutaminase coactivity. Since several reports suggest that L-glutamine depletion correlates with many of the side effects of these drugs, enzyme variants with reduced L-glutaminase coactivity might be clinically beneficial if their antileukemic activity would be preserved. Here we show that novel low L-glutaminase variants developed on the backbone of the FDA-approved Erwinia chrysanthemi L-asparaginase were highly efficacious against both T-and B-cell ALL, while displaying reduced acute toxicity features. These results support the development of a new generation of safer L-asparaginases without L-glutaminase activity for the treatment of human ALL. 
Significance: A newL-asparaginase-based therapy is less toxic compared with FDA-approved high L-glutaminase enzymes},
  author       = {Nguyen, Hien Anh and Su, Ying and Zhang, Jenny Yu and Antanasijevic, Aleksandar and Caffrey, Michael and Schalk, Amanda M and Liu, Li and Rondelli, Damiano and Oh, Annie and Mahmud, Dolores L and Bosland, Maarten C and Kajdacsy-Balla, Andre and Peirs, Sofie and Lammens, Tim and Mondelaers, Veerle and De Moerloose, Barbara and Goossens, Steven and Schlicht, Michael J and Kabirov, Kasim K and Lyubimov, Alexander V and Merrill, Bradley J and Saunthararajah, Yogen and Van Vlierberghe, Pieter and Lavie, Arnon},
  issn         = {0008-5472},
  journal      = {CANCER RESEARCH},
  keyword      = {CHRYSANTHEMI L-ASPARAGINASE,ACUTE LYMPHOCYTIC-LEUKEMIA,POLYETHYLENE-GLYCOL,CLINICAL-EVALUATION,ESCHERICHIA-COLI,CHILDREN,SYNTHETASE,TOXICITY,THERAPY,ENZYME},
  language     = {eng},
  number       = {6},
  pages        = {1549--1560},
  title        = {A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo},
  url          = {http://dx.doi.org/10.1158/0008-5472.can-17-2106},
  volume       = {78},
  year         = {2018},
}

Chicago
Nguyen, Hien Anh, Ying Su, Jenny Yu Zhang, Aleksandar Antanasijevic, Michael Caffrey, Amanda M Schalk, Li Liu, et al. 2018. “A Novel L-asparaginase with Low L-glutaminase Coactivity Is Highly Efficacious Against Both T- and B-cell Acute Lymphoblastic Leukemias in Vivo.” Cancer Research 78 (6): 1549–1560.
APA
Nguyen, H. A., Su, Y., Zhang, J. Y., Antanasijevic, A., Caffrey, M., Schalk, A. M., Liu, L., et al. (2018). A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo. CANCER RESEARCH, 78(6), 1549–1560.
Vancouver
1.
Nguyen HA, Su Y, Zhang JY, Antanasijevic A, Caffrey M, Schalk AM, et al. A novel L-asparaginase with low L-glutaminase coactivity is highly efficacious against both T- and B-cell acute lymphoblastic leukemias in vivo. CANCER RESEARCH. 2018;78(6):1549–60.
MLA
Nguyen, Hien Anh, Ying Su, Jenny Yu Zhang, et al. “A Novel L-asparaginase with Low L-glutaminase Coactivity Is Highly Efficacious Against Both T- and B-cell Acute Lymphoblastic Leukemias in Vivo.” CANCER RESEARCH 78.6 (2018): 1549–1560. Print.